Skip to main content

COVID-19 confirmed patients with negative antibodies results



A new coronavirus disease 2019 (COVID-19) has escalated to a pandemic since its first outbreak in Wuhan, China. A small proportion of patients may have difficulty in generating IgM or IgG antibodies against SARS-CoV-2, and little attention has been paid to them.

Case presentations

We present two cases of confirmed COVID-19 patients and characterize their initial symptoms, chest CT results, medication, and laboratory test results in detail (including RT-PCR, IgM/ IgG, cytokine and blood cell counts).


Both of patients with confirmed COVID-19 pneumonia failed to produce either IgM or IgG even 40 to 50 days after their symptoms onset. This work provides evidence demonstrating that at least a small proportion of patients may have difficulty in rapidly gaining immunity against SARS-CoV-2.

Peer Review reports


During the outbreak of coronavirus 2019 (COVID-19) [1,2,3], a small proportion of confirmed COVID-19 patients fail to produce IgM or IgG antibodies against SARS-CoV-2 even 40 days or longer periods of time after onset of their initial symptoms. However, most of the current studies so far are focused on the general population but for these patients.

From January 30 to March 15, 310 of COVID-19 patients who were positive for SARS-CoV-2 real time reverse-transcription PCR (RT-PCR) testing and received IgM and IgG detection at Wuhan Union Hospital (Wuhan, China) were enrolled. RT-PCR was performed through amplifying ORF1ab gene and N gene of SARS-CoV-2 (BioGerm, Shanghai, China) using oropharyngeal  swab specimens of all patients. From March 4 to 15, IgM and IgG of SARS-CoV-2 were tested using blood samples for all these 310 patients. Two different kits were used to detect antibodies through immune colloidal gold (ICG) technique (Yingnuote, Tangshan, China) and chemiluminescence immunoassay (CLIA) technique (Yahuilong, Shenzhen, China). Laboratory test results were collected and analyzed.

Among 310 COVID-19-confirmed patients, 308 of them were tested positive for IgM and/ or IgG, but only two patients were negative for IgM and IgG detection.

Case presentations

Case 1

Patient 1 (Fig. 1), a 29-year-old man, developed a cough and a sore throat with no fever on January 28. Ground-glass opacities in chest CT and positive RT-PCR test results were obtained on February 2 and 8, respectively. Four days later (February 12), this patient developed mild pneumonia and was hospitalized for treatment (600 mg of antiviral arbidol, orally, every 12 h). From February 14 to 17, four consecutive RT-PCR test results (every day) using his throat swab specimens were all negative. With remission of pneumonia symptoms and absorption of ground-glass opacities, the patient was discharged on February 21. However, on March 5, his RT-PCR test result was tested positive again during his follow-up, and he was hospitalized again in the next day. After two negative RT-PCR test results on March 10 and 12, the patient was discharged on March 15. No evidence showed that the patient’s immune function was compromised (Table 1). Analyses of a large range of laboratory results revealed that most of tests were normal, including the Immunoglobulin G, M, A (IgG, IgM, IgA) and Complement 3, 4 (C3, C4) (Table S1). IgM and IgG were repeatedly tested using his serum samples by two different detection methods (see Methods for details) on March 7 and 8, which were all negative.

Fig. 1

Chronology of symptom onset, hospital admission/ discharge, chest CT test, RT-PCR test and IgM/ IgG test

Table 1 Summary of Laboratory Examination Results of Two Patients

Case 2

Patient 2 (Fig. 1), a 58-year-old man, developed a fever and a cough on January 24 and were admitted to Wuhan Central Hospital on January 31. Multifocal ground-glass opacities were observed on chest CT images and the RT-PCR test for SARS-CoV-2 was positive on February 1. Despite anti-infection treatment and oxygen support, his symptoms worsened over the next few days, leading to severe pneumonia. On February 11, the patient was transferred to Wuhan Union Hospital for further treatment (400 mg of moxiflxacin, daily; 1000 mg of tienam, every 8 h; 200 mg of arbidol, every 8 h; 40 mg of methylprednisolone, every 12 h). The patient with glucocorticoid therapy showed reduced lymphocyte numbers and low ratios of CD3, CD4 and CD8 T cells (Table 1), suggesting his compromised immune functions. Elevated IL-6 level was related to his severe pneumonia as previously reported [4]. Moreover, 27 of 62 laboratory tests of this patient were abnormal, such as elevated levels of C-reactive protein (CRP), neutrophils and lactate dehydrogenase (LDH), and decreased levels of albumin, and hemoglobin (Table S2). On February 17 and March 11, he received two consecutive RT-PCR tests, which were positive. However, IgM and IgG in his serum samples remained undetectable on March 4, 9, and 14.

Discussion and conclusions

Serological tests have been widely utilized in the diagnosis of COVID-19. IgM could be detected as early as 1 day post- symptom onset (PSO) and was detectable in 85% of COVID-19 confirmed patients 7 days PSO [5]. As for IgG, over 90% of COVID-19 confirmed patients produced this type of antibody 14 days after illness [5]. In this study, two patients with confirmed COVID-19 failed to produce either IgM or IgG even 40 to 50 days after their symptoms onset. Given that all of COVID-19 patients reportedly had sero-positive for IgM and IgG approximately 35 days after symptoms onset [6], the window period for antibody production in these two COVID-19 patients may be much longer, possibly up to 50 days or even longer (if they eventually produce antibodies). These finding suggests that at least a small proportion of patients may have difficulty in rapidly gaining immunity against SARS-CoV-2. The cross-reactivity among different coronaviruses may lead to false-positive results in IgM and IgG detection [6], but few false-negative outcomes were yielded, especially jointly using CLIA and ICG techniques. Thus, the fact that two or three times of negative results in the two patients using two different kits suggests that the results are unlikely to be false-negative. Analyses of the laboratory results showed that the 58-year-old patient (Case 2) had compromised immune functions, which might contribute to the negative IgM/ IgG results. However, the young patient (Case 1), who possessed normal immune functions and did not have any underlying disease, yet fails to produce IgM/ IgG 40 days after symptom onset. The reason remains unclear.

A further long-term follow-up should be carried out for these patients to determine whether they produce IgM/ IgG or persistently remain with no antibodies. Additionally, recurrence of COVID-19 was observed in the 29-year-old patient. If our finding of pneumonia recurrence in COVID-19 patients without antibodies is replicated, the management of these no-antibody patients needs to be more cautious as they may be prone to recurrence or re-infection. In summary, this work presents two typical cases of COVID-19 patients without producing IgM/ IgG and comprehensively characterizes their initial symptoms, chest CT results, medication, and laboratory test results, hoping to draw more attentions to this type of patients.

Availability of data and materials

The data-sets used during the current study are available from the corresponding author on reasonable request.



Coronavirus disease 2019


Real-time polymerase chain reaction


Computed tomography


Immunoglobulin G antibodies


Immunoglobulin M antibodies


Immune colloidal gold


Chemiluminescence immunoassay


Post- symptom onset


  1. 1.

    Paules CI, Marston HD, Fauci AS. Coronavirus infections-more than just the common cold. JAMA. 2020;323(8):707–8.

    CAS  Article  Google Scholar 

  2. 2.

    Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–207.

    CAS  Article  Google Scholar 

  3. 3.

    Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9.

    CAS  Article  Google Scholar 

  4. 4.

    Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.

    CAS  Article  Google Scholar 

  5. 5.

    Theel ES, Slev P, Wheeler S, Couturier MR, Wong SJ, Kadkhoda K. The role of antibody testing for SARS-CoV-2: is there one? J Clin Microbiol. 2020;58(8):e00797–20.

  6. 6.

    Zhao J, Yuan Q, Wang H, et al. Antibody responsed to SARSCoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020.

Download references


We thank Xueping Wang and colleagues from Immunoassay Team of Clinical Laboratory for generously providing antibodies results of COVID-19 patients. We thank Fenghua Chen, Zhi Geng, Yang Liu, Qianwen Zhang and colleagues from Nucleic Acid Testing Team of Clinical Laboratory for generously providing RT-PCR test results of COVID-19 patients.


Not applicable.


No funding was received for this publication.

Author information




JW, CC and PC contributed to data collection. JW, ZW, LW and QL contributed to data analysis. All authors contributed to data interpretation. JW, ZW and LW drafted the manuscript. All authors critically commented on the manuscript and approved the final version.

Corresponding authors

Correspondence to Zheng Wang or Lin Wang.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Wuhan Union Hospital of Huazhong University of Science and Technology institutional review board and informed consent were waived.

Consent for publication

Written informed consent was obtained from the individuals for the publication of any potentially identifiable images or data included in this article.

Competing interests

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1: Table S1.

Laboratory Examination Results of Patient 1. Table S2. Laboratory Examination Results of Patient 2.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wang, J., Chen, C., Li, Q. et al. COVID-19 confirmed patients with negative antibodies results. BMC Infect Dis 20, 698 (2020).

Download citation


  • Case report
  • COVID-19
  • IgM
  • IgG
  • Negative antibodies results